Investor Relations

Company Overview

X4 is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4’s pipeline is comprised of first-in-class, oral, small molecule antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies, or PIs, and cancer. PIs are a group of more than 250 rare, chronic disorders in which flaws in the immune system cause increased susceptibility to infections and, in some cases, increased risk of cancers. Within this broad disease classification, a number of PIs are attributed to the improper trafficking of immune cells related to the CXCR4 receptor and its ligand CXCL12. X4’s lead product candidate, X4P-001, is in clinical development in patients with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis, or WHIM syndrome, a PI that is a genetic rare disease.
Investor Contact
Email Alerts
Email Page
Print Page
RSS Feeds